BiomX Ltd. is a clinical-stage biotechnology company developing targeted bacteriophage therapies designed to modulate the human microbiome. The company’s proprietary platform combines computational analytics with phage biology to identify and engineer virus-based agents that selectively target disease-associated bacteria without disrupting beneficial microbial communities. Through this precision approach, BiomX aims to address unmet needs in gastrointestinal and dermatological disorders driven by microbial dysbiosis.
BiomX’s pipeline includes investigational products for conditions such as Crohn’s disease, ulcerative colitis and acne. Lead programs employ phage cocktails tailored to reduce inflammation-associated bacteria in the gut, while dermatology candidates focus on skin-resident pathogens implicated in acne. Each program is supported by preclinical validation and, in some cases, early-stage clinical studies to assess safety, tolerability and preliminary signs of efficacy.
Founded in 2015 and headquartered in Rehovot, Israel, with a presence in the United States, BiomX leverages collaborations with academic institutions and strategic partners for phage discovery, manufacturing and clinical development. The company’s integrated R&D infrastructure spans computational biology, microbiology and translational research to accelerate its therapeutic ambitions across multiple geographies.
BiomX’s leadership team comprises experts in microbiology, immunology and pharmaceutical development who bring extensive experience from both industry and academic settings. With a focus on expanding its proprietary platform, the company continues to explore new indications and phage combinations aimed at delivering targeted, microbiome-based treatments for patients worldwide.
AI Generated. May Contain Errors.
